Status:
COMPLETED
Contrast-enhanced Ultrasound With Perfluorobutane and Sulfur Hexafluoride for Hepatocellular Carcinoma
Lead Sponsor:
Seoul National University Hospital
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Intra-individual comparison of diagnostic performance of CEUS With perfluorobutane and sulfur hexafluoride for HCC in high-risk Individuals, and their role in the diagnostic algorithm of HCC.
Detailed Description
The investigators would compare the diagnostic performance for HCC at high-risk individuals between both USG contrast agents.
Eligibility Criteria
Inclusion
- high-risk for HCC (liver cirrhosis, chronic hepatitis B)
- treatment-naive hepatic nodule (\>= 1cm) on preceding CT, MR or ultrasound
Exclusion
- severe cardiopulmonary dysfunction
- pregnancy
- refusal to enroll study
Key Trial Info
Start Date :
June 9 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 30 2021
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT04847726
Start Date
June 9 2020
End Date
October 30 2021
Last Update
December 7 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, Jongno-gu, South Korea, 03038